Executive interview – VolitionRx Third Quarter 2018 Earnings Review

Executive interview – VolitionRx Third Quarter 2018 Earnings Review

Volition is a multi-national life sciences company focused on developing simple, easy to use, cost effective blood tests designed to help diagnose a range of cancers. The tests are based on the technology platform of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.


You may also be interested in these:

Real Estate

Foxtons - executive interview

The Platform Group ETV

Consumer

The Platform Group - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free